Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL28135924 | 0.96 | ALDH1A1 (0.59) | CYP2D6CYP2C19CYP1A2CYP2C9TSHR | |
| SCHEMBL3056874 | 0.87 | KMT2A (0.71) | CYP2D6CYP2C19CYP1A2CYP2C9TSHR | |
| SCHEMBL2746268 | 0.85 | ALDH1A1 (0.56) | CYP2D6CYP2C19CYP1A2CYP2C9TSHR | |
| SCHEMBL81511 | 0.83 | CYP2C19 (0.64) | CYP2D6CYP2C19CYP1A2CYP2C9TSHR | |
| SCHEMBL1867492 | 0.83 | ALDH1A1 (0.61) | CYP2D6CYP2C19CYP1A2CYP2C9TSHR | |
| SCHEMBL15808527 | 0.82 | CA2 (0.50) | CYP2C19CYP2C9KMT2AMEN1 | |
| SCHEMBL881512 | 0.82 | KMT2A (0.61) | CYP2D6CYP2C19CYP1A2CYP2C9TSHR | |
| SCHEMBL5814043 | 0.81 | ALDH1A1 (0.56) | CYP2D6CYP2C19CYP1A2CYP2C9TSHR | |
| SCHEMBL13700867 | 0.81 | ALDH1A1 (0.51) | CYP2D6CYP2C19CYP1A2CYP2C9TSHR | |
| Hydrochloric Acid SCHEMBL17710406 | 0.81 | CYP2C19 (0.62) | CYP2D6CYP2C19CYP1A2CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385948-B1 | FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TORRENT PHARMACEUTICALS LTD (IN) | 2017-10-04 | — | — | EP | claimed |
| CN-107021943-A | One class 7-epi- baccatin III derivatives, and its production and use | 中国科学院上海药物研究所 | 2017-08-08 | — | — | CN | claimed |
| US-20130331406-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TORRENT PHARMACEUTICALS LIMITED (IN) | 2013-12-12 | — | — | US | claimed |
| US-8541430-B2 | Fused thiazolo and oxazolo pyrimidinones | TORRENT PHARMACEUTICALS LIMITED (IN) | 2013-09-24 | — | — | US | claimed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| CN-108025189-B | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 美国陶氏益农公司 | 2021-07-02 | — | — | CN | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| EP-2385948-B1 | FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TORRENT PHARMACEUTICALS LTD (IN) | 2017-10-04 | — | — | EP | disclosed |
| EP-2462141-B1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-20040011252-A1 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON | 2004-01-22 | — | — | US | disclosed |
| US-20030234063-A1 | Non-toxic corrosion-protection conversion coats based on cobalt | DAYTON, UNIVERSITY OF | 2003-12-25 | — | — | US | disclosed |
| US-20030230363-A1 | Non-toxic corrosion-protection rinses and seals based on cobalt | UNIVERSITY OF DAYTON | 2003-12-18 | — | — | US | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060191-A2 | NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060019-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2002076968-A1 | MALONATES AS INHIBITORS OF THE ICE/CED-6 FAMILY OF CYSTEINE PROTEASES | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
| WO-1994027958-A1 | 4-AMIDINOPHENYLSULPHONAMIDES FOR THE TREATMENT OF THROMBO-EMBOLITIC CONDITIONS | BOEHRINGER MANNHEIM GMBH (DE) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | CYP2D6 2732/4885CYP2C19 2449/4885CYP1A2 3232/4885 |
| US-20130331406-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TPMT, TYMS, UGT1A8 | CYP2D6 33/4885CYP2C19 54/4885CYP1A2 64/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | CYP2D6 2732/4885CYP2C19 2449/4885CYP1A2 3232/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | CYP2D6 2732/4885CYP2C19 2449/4885CYP1A2 3232/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | CYP2D6 979/4885CYP2C19 1443/4885CYP1A2 2368/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | CYP2D6 2732/4885CYP2C19 2449/4885CYP1A2 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.